- Title: Subtitle
- Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period
- Creators
- Dieter Hörsch - Zent Klin Bad Berka, Bad Berka, GermanyMatthew H. Kulke - Dana-Farber Cancer InstituteMartyn E. Caplin - The Royal Free HospitalLowell B. Anthony - University of KentuckyEmily Bergsland - UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USAKjell Öberg - Uppsala UniversityRichard R. P. Warner - Icahn School of Medicine at Mount SinaiPamela L. Kunz - Stanford UniversityEnrique Grande - Hosp Ramon & Cajal, Madrid, SpainJuan W. Valle - University of ManchesterJoseph S. Dillon - University of IowaPablo Lapuerta - Lexicon Pharmaceut Inc, The Woodlands, TX, USAPhillip Banks - Lexicon Pharmaceut Inc, The Woodlands, TX, USAShanna Jackson - Lexicon Pharmaceut Inc, The Woodlands, TX, USAMarianne Pavel
- Resource Type
- Abstract
- Publication Details
- Pancreas, Vol.47(3), p.341
- DOI
- 10.1097/MPA.0000000000000997
- ISSN
- 0885-3177
- eISSN
- 1536-4828
- Language
- English
- Date published
- 2018
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984361729902771
Abstract
Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period
Pancreas, Vol.47(3), p.341
2018
DOI: 10.1097/MPA.0000000000000997
Abstract
Details
Metrics
3 Record Views